COMP360 FOR TREATMENT RESISTANT DEPRESSION

This is a  study to investigate the efficacy, safety and tolerability of COMP360 (psilocybin) in participants with treatment resistant depression (TRD). Administered under supportive conditions to adults participants with treatment resistant depression.

PI: Ryan Wagoner, MD

Study Coordinator - Caroline Swade (813) 440-9444 | cswade@usf.edu

Back-up SC - Mariah Nelson, RN (813) 440-9428 | mariahn@usf.edu

_______________________________________________________________________________

COMP360 FOR TREATMENT RESISTANT DEPRESSION (005 Study)

This is a placebo controlled study to investigate the efficacy, safety and tolerability of COMP360 (psilocybin) in participants with treatment resistant depression (TRD). Administered under supportive conditions to adult participants with treatment resistant depression.

Pl - Ryan Wagoner, MD

Study Coordinator- Mariah Nelson, RN, BSN (813) 440-9428 | mariahn@usf.edu

___________________________________________________________________________________

MDD 3001 DEPRESSION

This is a 12-week study to see if the investigational drug, also known as aticaprant, added to current antidepressant is safe and would help improve symptoms in participant with major depressive disorder with moderate to severe anhedonia and inadequate response to current antidepressant therapy.

Pl - Daniel Fallon, MD

Study Coordinator- Jordan Belliamy, MPH (813) 618-1074 | jbelliamy@usf.edu

______________________________________________________________________________________

Coming soon

• Psilocybin in Post-Partum 

ALZHEIMER’S DISEASE VACCINE STUDY

A 28-week study to evaluate safety and efficacy of vaccine, AV-1959D, in patients with Mild Cognitive Impairment, Alzheimer’s type or early onset Alzheimer’s disease. Eligible patients will be 60 to 85 years of age, in good general health, have a diagnosis of Alzheimer’s disease, and have a partner or caregiver to accompany to study visits.

PI: Ram, Bischoi, MD

Study Coordinator: Angela McDowell - (813) 440-9438 | angelamcdowell@usf.edu

AUTISM SPECTRUM DISORDER AGES 12-45 YEARS - SOCIAL COMMUNICATION AND IRRITABILITY STUDY

This is a 25-week study to investigate the efficacy, safety and tolerability of an investigational medication, ML-004 in adolescents and adults with autism spectrum disorders (ASD) for improvement of social communication, social deficits, and irritability symptoms associated with Autism Spectrum Disorder. 

PI: Daniel Fallon, MD

Study Coordinator: Ahsan Qadir - (813) 440-9440 | aqadir@usf.edu

CARIPRAZINE FOR TREATMENT OF BIOPOLAR I, DEPRESSION IN 10-17 YEAR OLDS

This is a 6-week study to evaluate the effectiveness and safety of Cariprazine versus placebo in children and adolescents age 10-17 years who are currently experiencing a depressive episode.

PI: Daniel Fallon, MD

Study Coordinator:  Ahsan Qadir - (813) 440-9440 | aqadir@usf.edu